CA2749261A1 - Combination therapies for neoplastic disorders - Google Patents

Combination therapies for neoplastic disorders Download PDF

Info

Publication number
CA2749261A1
CA2749261A1 CA2749261A CA2749261A CA2749261A1 CA 2749261 A1 CA2749261 A1 CA 2749261A1 CA 2749261 A CA2749261 A CA 2749261A CA 2749261 A CA2749261 A CA 2749261A CA 2749261 A1 CA2749261 A1 CA 2749261A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
independently
heteroalkyl
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2749261A
Other languages
English (en)
French (fr)
Inventor
Denis Drygin
Caroline B. Ho
Joshua R. Bliesath
Christopher B. Proffitt
Sean O'brien
Kenna Anderes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CA2749261A1 publication Critical patent/CA2749261A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2749261A 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders Abandoned CA2749261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
US61/143,282 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
CA2749261A1 true CA2749261A1 (en) 2010-07-15

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2749261A Abandoned CA2749261A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Country Status (13)

Country Link
EP (1) EP2381942A1 (ja)
JP (1) JP2012514638A (ja)
KR (1) KR20110116153A (ja)
CN (1) CN102341107A (ja)
AU (1) AU2009336141A1 (ja)
BR (1) BRPI0924041A2 (ja)
CA (1) CA2749261A1 (ja)
IL (1) IL213969A0 (ja)
MX (1) MX2011007384A (ja)
RU (1) RU2011133093A (ja)
SG (1) SG172922A1 (ja)
WO (1) WO2010080170A1 (ja)
ZA (1) ZA201105755B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
WO2020081971A1 (en) * 2018-10-19 2020-04-23 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN114869903A (zh) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661842C (en) * 2006-09-01 2017-08-22 Cylene Pharmaceuticals, Inc. Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
CN102341107A (zh) 2012-02-01
JP2012514638A (ja) 2012-06-28
SG172922A1 (en) 2011-08-29
MX2011007384A (es) 2011-12-14
AU2009336141A1 (en) 2011-08-11
ZA201105755B (en) 2012-04-25
WO2010080170A1 (en) 2010-07-15
IL213969A0 (en) 2011-08-31
EP2381942A1 (en) 2011-11-02
RU2011133093A (ru) 2013-02-20
BRPI0924041A2 (pt) 2016-01-26
KR20110116153A (ko) 2011-10-25

Similar Documents

Publication Publication Date Title
US20100173013A1 (en) Treatment of neoplastic disorders using combination therapies
AU2017254687A1 (en) Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
CN106413716A (zh) 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
CA3172088A1 (en) Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
ZA200402812B (en) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine A2a receptor antagonists.
US20100267753A1 (en) Methods of treating disorders associated with protein kinase ck2 activity
EA015779B1 (ru) Соединения для ингибирования митоза
EP4021907A1 (en) Triazolopyrimidines as a2a / a2b inhibitors
CN107667092A (zh) 作为fgfr4抑制剂的甲酰化n‑杂环衍生物
AU2019388843B2 (en) An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
AU2019355057A1 (en) Method for preparing and delivering bisantrene formulations
CA2749261A1 (en) Combination therapies for neoplastic disorders
CN114028406A (zh) 阿尔茨海默疾病或痴呆预防、治疗或拖延用药学组合物
JP7329509B2 (ja) 中枢および末梢神経系障害の治療のためのキナーゼ阻害剤
US20210299111A1 (en) Eif4a inhibitor combinations
CN114957296A (zh) 一类新型阿尔茨海默病检测探针及其生物应用
KR20240031149A (ko) 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법
WO2020063860A1 (en) Naphthyridinone and pyridopyrimidinone compounds useful as kinases inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140610